Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Value investment firm Brandes Investment Partners, L.P., announced today that Charles Brandes, CFA, will present at the inaugural Asia Value Investor Conference in Hong Kong on December 8, 2015....
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®)...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy...